This guidance will partially update the following:
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6434
Provisional Schedule
- Expected publication:
- 18 September 2025
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Pfizer (lorlatinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- ALK Positive UK
- Oncogene Cancer Research
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Comparator companies
- Roche (alectinib)
- Takeda (brigatinib)
- General commentators
- All Wales Therapeutic and Toxicology Centre
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 July 2025 | Committee meeting: 2 |
| 09 April 2025 - 02 May 2025 | Draft guidance |
| 12 March 2025 | Committee meeting |
| 12 March 2025 | Declaration of interests |
| 10 July 2024 | Invitation to participate |
| 10 July 2024 | In progress. Invitation to Participate |
| 18 June 2024 - 02 July 2024 | Review proposal consultation |
| 25 June 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual